Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 623-633
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Table 3 Tumour characteristics of hepatocellular carcinoma cases
| HCC (n = 30) | ||
| Size | < 2 cm | 3 (10%) |
| 2-3 cm | 17 (56.7%) | |
| > 5 cm | 10 (33.3%) | |
| Number of tumour foci | Single | 10 (33.3%) |
| 2-3 | 9 (30%) | |
| Multiple | 11 (36.7%) | |
| Portal vein thrombosis | No | 21 (70%) |
| Yes | 9 (30%) | |
| Metastasis | No | 27 |
| Yes | 3 | |
- Citation: Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.623